Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2009

Centocor to Optimize Its Antibody Candidates Using Xencor’s Technology

  • Xencor licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development for the optimization of Centocor’s antibody drug candidates. Under the multiyear agreement, Centocor will gain access to both the XmAb and Xtend technology platforms and has the right to develop and commercialize a specified number of optimized candidates. Xencor will receive license fees and is eligible to receive milestones and royalties on products commercialized from the collaboration.

    Xtend antibody technology platform helps enhance the serum half-life of immunoglobulin molecules. The XmAb platform can increase the potency of therapeutic antibodies by specifically engaging the body’s immune system against target antigen cells, according to Xencor.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »